Full Press Release Details
Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
Limited (Stock Code: 500124)
York Stock Exchange Inc. (Stock Code: RDY)
IFSC Ltd. (Stock Code: DRREDDY)
Intimation of Earnings call
find enclosed a notification titled "Dr. Reddy's to release Q2FY25 results on Tuesday, November 5th, 2024 Earnings call slated
for Tuesday, November 5th @19:30 PM IST / 9:00 AM ET."
is for your information and records.
Dr. Reddy's Laboratories Limited
Secretary, Compliance Officer & Head-CSR
| CONTACT | |||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS | |
| 8-2-337, Road No. 3, Banjara Hills, | Richa Periwal | richaperiwal@drreddys.com | USHA IYER |
| Hyderabad - 500034, Telangana, India. | AISHWARYA SITHARAM | aishwaryasitharam@drreddys.com | ushaiyer@drreddys.com |
Reddy's to release Q2FY25 results on Tuesday, November 5th, 2024
call slated for Tuesday, November 5th
India, October 21st, 2024
Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the quarter and six months
ended September 30th, 2024 on Tuesday, November 5th, 2024 after the Board Meeting.
| Event | Date and Time | Medium |
| Release of financial results | November 5 th , 2024, after the Board Meeting | Stock Exchange, Media, Company Website, Email |
| Press Meet Presentation | Will be available on the Company's Website | Company's Website www.drreddys.com |
| Earnings Call | November 5 th , 19:30 PM IST / 9:00 AM ET | Hosted by the Company (Details below) |
| Playback of Earnings Call | After the earnings call till November 11 th , 2024 | Details below |
| Audio as well as Transcript of the Earnings call | Will be available on the Company's Website | Company's Website www.drreddys.com |
Following the release, the management of the Company
will host its earnings call to discuss the Company's financial performance. (Dial-in and other details given below)
The play back will be available after the earnings
call till November 11th, 2024.
For play back, dial in phone no.: +91 22 7194
5757, and playback code is 03706.
Conference Joining Information
Option 1: Express Join with DiamondPass
Pre-register with the below link and join without waiting for the operator.
| Option 2: Join through below Dial-In Numbers | |
| Universal Access Number: | +91 22 6280 1219 +91 22 7115 8120 |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in
to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical
company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines.
Driven by our purpose of Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics,
branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology,
pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe.
As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses
of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current
ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For
more information, log on to:www.drreddys.com.
This press release may include statements of future expectations and other forward-looking statements that are based on the management's
current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events
to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason
of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults
, currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in
the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues,
and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic
downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and
(vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed
under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year
ended March 31, 2024. The company assumes no obligation to update any information contained herein." The company assumes no obligation
to update any information contained herein.